“Our Mission: Developing Superior Protection from Pulmonary Embolisms”
Crux Biomedical, Inc., was formed in 2004 by physicians Tom Fogarty and Frank Arko based upon their observations of the clinical limitations of current vena cava filters. Supported by venture backed funding led by Alloy Ventures (Menlo Park, CA) and Emergent Medical Partners (Portola Valley, CA), the company’s mission is to develop a revolutionary retrievable inferior vena cava filter (IVCF) to prevent pulmonary embolism (PE).
Crux has been awarded four US patents (7,582,100, 7,785,343, 7,789,892, 7,854,747) for its unique filter technology. “We are very pleased with the issuance of these comprehensive patents. The Crux technology is applicable for a breadth of treatments in the human vasculature”, stated Mel Schatz, CEO of Crux Biomedical.
The company has FDA approval for an IDE (Investigational Device Exemption) study in the US. The company will be including investigational sites outside the US in parallel protocols. The RETRIEVE studies are anticipated to conclude enrollment in mid-2011, along with two studies outside the U.S.